EMA Authorised: Pifeltro (doravirine) — Merck Sharp & Dohme B.V.

View source ↗

Summary

The European Medicines Agency authorised Pifeltro (doravirine) for HIV infections, marking EU marketing authorization for this antiretroviral agent.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• PIFELTRO (doravirine)

Snippet

Status: Authorised. Therapeutic area: HIV Infections. MAH: Merck Sharp & Dohme B.V.. Decision date: 16/10/2025